

8PP

RECEIVED
OPPT CBIC

06 MAY 17 AM 6:00

8EHQ-0506-00394

AR226-3658

DuPont Haskell Laboratory
for Health and Environmental Sciences
Elkton Road, P.O. Box 50
Newark, DE 19714-0050

May 15, 2006

Via Federal Express

Document Processing Center (Mail Code 7407M)
Room 6428
Attention: 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
1201 Constitution Ave., NW
Washington, DC 20460

8EHP-81-394

CONTAIN NO CBI

Dear 8(e) Coordinator:

8EHQ-0381-0394
Perfluorooctanoate (PFOA)

This letter is being submitted as a supplement to our PFOA epidemiology submissions we communicated to the Agency on January 10 and August 4, 2005.

Enclosed please find the results of a longitudinal study of serum total cholesterol related to serum PFOA measurements in a group of Washington Works employees that participated at least twice in the voluntary biomonitoring program at the plant over the last 25 years. Using a mixed effects statistical model with repeated measures for the 454 employees with at least two measurements of PFOA, the essential results show an increase of total cholesterol with increasing serum PFOA of about 1 mg/dl cholesterol per 1 ppm PFOA. The major limitations of the study were the lack of information regarding the use and/or start and stop dates of lipid-lowering medications, and the necessity of interpolating cholesterol results between dates of PFOA monitoring.

The enclosed poster was presented last week at the American College of Occupational and Environmental Medicine (ACOEM) conference.

While DuPont does not believe this information is substantial risk information reportable under TSCA 8(e), DuPont is submitting the information to the TSCA 8(e) office in view of the Agency's continued interest in perfluorinated substances.

Sincerely,

A. Michael Kaplan, Ph.D.
Director - Regulatory Affairs and Occupational Health

Enclosure: (1)

AMK/RWR/RCL: clp
(302) 366-5260

2006 MAY 19 PM 2:16

RECEIVED
OPPT CBIC